No abstract

10-year actuarial risk of 20.7%, 36%, 45.3%, respectively (log-rank p<0.01). Multivariate analysis found that the percentage of the dose delivered with electrons and the PTV volume receiving 95% of the total dose (V95%) were significantly associated with the risk of fibrosis. Conclusion: There were no significant differences in local failure rates between 32 Gy, 36 Gy or 40 Gy delivered in twice-daily 4-Gy fractions. However, rates of moderate or severe fibrosis and worse cosmetic outcome significantly increased for patients treated to the two higher doses. These findings suggest that 32 Gy in 8 fractions may be an optimal dose for appropriate patients when APBI is administered using twice daily fractionation.

No abstract